Andy Chen
Stock Analyst at Wolfe Research
(4.64)
# 845
Out of 4,531 analysts
70
Total ratings
67.3%
Success rate
30.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Downgraded: Hold | n/a | $54.39 | - | 3 | Jul 15, 2026 | |
| NTLA Intellia Therapeutics | Downgraded: Sell | $9 | $11.38 | -20.88% | 5 | Jul 15, 2026 | |
| SRPT Sarepta Therapeutics | Upgraded: Buy | $27 | $17.22 | +56.79% | 2 | Jul 8, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $44 | $35.35 | +24.47% | 4 | Jun 14, 2026 | |
| ABVX ABIVAX Société Anonyme | Rated: Buy | $176 → $136 | $136.65 | -0.48% | 2 | Jun 3, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $88 | $38.50 | +128.57% | 4 | Jun 2, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $7 | $1.97 | +255.33% | 1 | Apr 8, 2026 | |
| AVTX Avalo Therapeutics | Initiated Coverage: Buy | $48 | $19.37 | +147.81% | 1 | Apr 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $98 | $105.60 | -7.20% | 1 | Apr 8, 2026 | |
| PHVS Pharvaris | Initiated Coverage: Buy | $42 | $34.94 | +20.21% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $40.26 | +16.74% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $24 | $19.68 | +21.95% | 5 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $134.00 | - | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $553.48 | - | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $548 | $485.65 | +12.84% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $115.77 | - | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $860.55 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $4.62 | +181.39% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $173 | $108.32 | +59.71% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $267.47 | - | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $81.38 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $58.00 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $117.25 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $100.23 | n/a | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $92.70 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $83.86 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $29.53 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $18.03 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $47.78 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $34.51 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $7.53 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.000001 | n/a | 2 | Aug 10, 2023 |
Ionis Pharmaceuticals
Jul 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $54.39
Upside: -
Intellia Therapeutics
Jul 15, 2026
Downgraded: Sell
Price Target: $9
Current: $11.38
Upside: -20.88%
Sarepta Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $27
Current: $17.22
Upside: +56.79%
Celldex Therapeutics
Jun 14, 2026
Maintained: Buy
Price Target: $44
Current: $35.35
Upside: +24.47%
ABIVAX Société Anonyme
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $136.65
Upside: -0.48%
Vera Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $88
Current: $38.50
Upside: +128.57%
Palisade Bio
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.97
Upside: +255.33%
Avalo Therapeutics
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $19.37
Upside: +147.81%
Dianthus Therapeutics
Apr 8, 2026
Maintained: Buy
Price Target: $98
Current: $105.60
Upside: -7.20%
Pharvaris
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $34.94
Upside: +20.21%
Apr 6, 2026
Maintained: Buy
Price Target: $47
Current: $40.26
Upside: +16.74%
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $19.68
Upside: +21.95%
Jan 7, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $134.00
Upside: -
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $553.48
Upside: -
Jan 6, 2026
Upgraded: Buy
Price Target: $548
Current: $485.65
Upside: +12.84%
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $115.77
Upside: -
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $860.55
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $4.62
Upside: +181.39%
Aug 14, 2025
Maintained: Buy
Price Target: $54 → $173
Current: $108.32
Upside: +59.71%
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $267.47
Upside: -
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $81.38
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $58.00
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $84
Current: $117.25
Upside: n/a
Mar 17, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $100.23
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $92.70
Upside: n/a
Feb 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $83.86
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $29.53
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $18.03
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $47.78
Upside: n/a
Feb 14, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $34.51
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $4
Current: $7.53
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.000001
Upside: n/a